

ARK:jsg030905/4781012DIV.AMD-2

IN THE CLAIMS:

Claims 1-47 (canceled without prejudice).

Claim 48 (currently amended): A method of evaluating and/or predicting the effect of a Specific Allergy Vaccination treatment comprising the steps of:

(h') determining the content of an antibody in a liquid sample using the following assay;

(a') providing a mixture of a liquid phase and a three-component solid phase complex composed of (i) the antibody of the sample, (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle, and (iii) a ligand in the form of an antigen, an antibody or a hapten, where component (i) binds to components (ii) and (iii),

(b') separating the three-component solid phase complex from the liquid phase,

(c') washing the separated three-component solid phase complex to remove non-complex bound compounds,

(d') adding to the three-component solid phase complex a solution of (iv) a label compound to form a four-component complex, where component (iv) binds to component (i), (ii) or (iii).

(e') separating the four-component solid phase complex from the solution,

(f') washing the separated four-component solid phase complex to remove non-complex bound label compound (iv),

ARK:jsg030905/4781012DIV.AMD-2

(g') performing a ~~detection/measurement~~ detection and/or measurement of the washed labeled four-component complex.

(i') determining the content of the said antibody using the following assay;

(ia') providing a mixture of a liquid phase and a four-component solid phase complex composed of (i) the antibody of the sample, (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle, (iii) a ligand in the form of an antigen, an antibody or a hapten, and (iv) a label compound, to form a four-component solid phase complex, where component (i) binds to components (ii) and (iii), and where component (iv) binds to component (i), (ii) or (iii),

(ib') separating the four-component solid phase complex from the liquid phase,

(ic') washing the separated four-component solid phase to remove non-complex bound compounds, and

(id') performing a ~~detection/measurement~~ detection and/or measurement of the washed labeled four-component complex.

(j') comparing the detection and/or measurements obtained in step (h') and step (i') and using the comparison to evaluate and/or predict the effect of the Specific Allergy Vaccination treatment, wherein an effect is obtained if the detection and/or measurement in step (i') is less than the detection and/or measurement in step (h').

ARK:jsg030905/4781012DIV.AMD-2

Claims 49 – 53 (canceled without prejudice)..

Claim 54 (currently amended): [A] The method according to claim 48, wherein step (ia') is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv), ~~if added~~.

Claims 55 - 59 (canceled without prejudice).

Claim 60 (currently amended): [A] The method according to claim 48, wherein step (ia'), is carried out by mixing components (i), (ii) and (iii), and then adding component (iv), ~~if added~~.

Claims 61 – 65 (canceled without prejudice).

Claim 66 (previously presented): [A] The method according to claim 48, wherein the comparison of step (j') is carried out by calculating the ratio of the measurements obtained in the two said steps.

Claims 67 – 71 (canceled without prejudice).

Claim 72 (currently amended): [A] The method according to claim 48, wherein the comparison of step (j') is carried out ~~in at a number of~~ at least one points in time ~~at the start of and during the treatment period~~, and that any temporal change,

ARK:jsg030905/4781012DIV.AMD-2

which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.

Claims 73 – 98 (canceled without prejudice).

Claim 99 (currently amended): [A] The method according to claim 48, wherein in step (a') and in step (ia') the ligand is bound to biotin or a functional derivative thereof, and

wherein in step (d') and in step (ia') the label compound is a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof, and wherein in step (g') and in step (id') the detection/measurement detection and/or measurement step comprises initiating a chemiluminescent reaction in the washed four-component solid phase complex and detecting/measuring detecting and/or measuring the resulting chemiluminescence.

Claim 100 (currently amended): [A] The method according to claim 99, wherein in step (a') and in step (ia') the solid particle is a solid paramagnetic particle, and  
wherein step (b'), step (e') and step (ib') comprise magnetically separating the solid phase complex from the liquid phase.

Claim 101 (currently amended): [A] The method according to claim 99 wherein step (ia') is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv).

ARK:jsg030905/4781012DIV.AMD-2

Claim 102 (currently amended): [A] The method according to claim 100 wherein step (ia') is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv).

Claim 103 (currently amended): [A] The method according to claim 99, wherein step (ia'), is carried out by mixing components (i), (ii) and (iii), and then adding component (iv).

Claim 104 (currently amended): [A] The method according to claim 100, wherein step (ia'), is carried out by mixing components (i), (ii) and (iii), and then adding component (iv).

Claim 105 (currently amended): [A] The method according to claim 99, wherein the comparison of step (j') is carried out by calculating the ratio of the measurements obtained in the two said steps.

Claim 106 (currently amended): [A] The method according to claim 100, wherein the comparison of step (j') is carried out by calculating the ratio of the measurements obtained in the two said steps.

Claim 107 (currently amended): [A] The method according to claim 99, wherein the comparison of step (j') is carried out ~~in at a number of least one point in time at the start of and during the treatment period, and that any temporal change,~~

ARK:jsg030905/4781012DIV.AMD-2

which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.

Claim 108 (currently amended): [A] The method according to claim 100, wherein the comparison of step (j') is carried out in at a number of least one points in time ~~at the start of and~~ during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.

Claim 109 (previously presented): The method according to claim 99, wherein the sample antibody is IgE.

Claim 110 (previously presented): The method according to claim 100, wherein the sample antibody is IgE.